dementia

Six in 10 people living with the Alzheimer's disease will wander off at some point.

In a health care system that assumes older adults have family caregivers to help them, those facing dementia by themselves often fall through the cracks.

Verbal, physical, and sexual aggression among dementia patients in long-term care facilities are alarmingly common. “There is a real problem with endemic violence,” one researcher says.

FDA approval is required to make Alzheimer's biomarker testing affordable, but a brain specialist is needed to make an accurate diagnosis.

The disease requires a brain scan or spinal tap to spot one sticky amyloid protein. But a recent study finds that a certain blood test helped improve diagnosis without more costly follow-up procedures.

The GUIDE Model is designed to facilitate comprehensive, coordinated care that improves the quality of life for people with dementia and reduces the strain on their unpaid caregivers.

The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.

A 2023 Alzheimer's Association report notes that 70% of caregivers say coordinating care is stressful. Three out of four say they are concerned for their own health given the stress and difficulty of the job.

A neurologist and neuropathologist address the prevalence, risk factors, early detection signs and preventive measures related to brain diseases.

The FDA will make the final decision on approval later this year. If the agency agrees with advisers, donanemab would only be the second drug approved to slow cognitive decline due to Alzheimer’s.